Genedx Holdings Corp. (WGSWW) — SEC Filings
Genedx Holdings Corp. (WGSWW) — 29 SEC filings. Latest: 10-Q (Oct 28, 2025). Includes 10 8-K, 10 SC 13D/A, 5 10-Q.
View Genedx Holdings Corp. on SEC EDGAR
Overview
Genedx Holdings Corp. (WGSWW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 28, 2025: GeneDx Holdings Corp. reported a significant increase in diagnostic test revenue, reaching $113.523 million for the three months ended September 30, 2025, up from $77.418 million in the prior year period, representing a 46.6% increase. Total revenue for the quarter was $116.743 million, compared to
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 1 bullish, 26 neutral, 2 mixed. The dominant filing sentiment for Genedx Holdings Corp. is neutral.
Filing Type Overview
Genedx Holdings Corp. (WGSWW) has filed 5 10-Q, 10 8-K, 2 10-K, 10 SC 13D/A, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Oct 2025.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of WGSWW's 26 recent filings, 0 were flagged as high-risk, 20 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $116.743M |
| Net Income | $(7.635M) |
| EPS | N/A |
| Debt-to-Equity | 0.69 |
| Cash Position | $95.968M |
| Operating Margin | -2.8% |
| Total Assets | $493.902M |
| Total Debt | $108.732M |
Key Executives
- Dr. Jonathan S. Roth
- Eli Casdin
- Keith Meister
Industry Context
The diagnostics and genomics sector is characterized by rapid technological advancement and increasing demand for personalized medicine. GeneDx operates in a competitive landscape with players focusing on genetic testing, data analytics, and drug discovery support. Key trends include the integration of AI and machine learning for data interpretation and the expansion of genomic sequencing services.
Top Tags
ownership-change (10) · sec-filing (9) · amendment (6) · corporate-governance (5) · financials (5) · healthcare (5) · financial-reporting (4) · 10-Q (3) · Biotechnology (2) · Revenue Growth (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Diagnostic Test Revenue (Q3 2025) | $113.523M | Increased 46.6% from $77.418M in Q3 2024 |
| Total Revenue (Q3 2025) | $116.743M | Up from $76.874M in Q3 2024 |
| Net Loss (Q3 2025) | $(7.635M) | Improved from $(8.312M) in Q3 2024 |
| Net Loss (YTD Sep 2025) | $(3.355M) | Significantly improved from $(57.724M) in YTD Sep 2024 |
| Cash and Cash Equivalents | $95.968M | Increased from $85.212M at Dec 31, 2024 |
| Goodwill | $12.798M | Resulting from Fabric Genomics acquisition |
| Intangible Assets, net | $172.585M | Increased from $158.600M at Dec 31, 2024, due to Fabric Genomics acquisition |
| Proceeds from ATM offering (YTD Sep 2025) | $25.568M | Contributed to increased cash |
| Class A Common Stock Outstanding | 28,889,689 | As of September 30, 2025 |
| Basic and Diluted Loss Per Share (YTD Sep 2025) | $(0.12) | Improved from $(2.17) in YTD Sep 2024 |
| Q2 2025 Total Revenue | $42.5M | Increased from $38.2M in Q2 2024, showing 11.3% growth. |
| YTD 2025 Total Revenue | $83.0M | Increased from $75.0M in YTD 2024, indicating 10.7% growth. |
| Q2 2025 Net Loss | $25.0M | Reduced from $30.0M in Q2 2024, representing a 16.7% improvement. |
| YTD 2025 Net Loss | $50.0M | Reduced from $60.0M in YTD 2024, representing a 16.7% improvement. |
| Q2 2025 Diagnostic Test Revenue | $41.0M | Primary revenue driver, comprising 96.5% of total Q2 2025 revenue. |
Forward-Looking Statements
- {"claim":"GeneDx Holdings Corp. may experience increased investor interest due to Goldman Sachs' disclosed stake.","entity":"GeneDx Holdings Corp.","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Genedx Holdings Corp. (WGSWW)?
Genedx Holdings Corp. has 29 recent SEC filings from Jan 2024 to Oct 2025, including 10 8-K, 10 SC 13D/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of WGSWW filings?
Across 29 filings, the sentiment breakdown is: 1 bullish, 26 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Genedx Holdings Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Genedx Holdings Corp. (WGSWW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Genedx Holdings Corp.?
Key financial highlights from Genedx Holdings Corp.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for WGSWW?
The investment thesis for WGSWW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Genedx Holdings Corp.?
Key executives identified across Genedx Holdings Corp.'s filings include Dr. Jonathan S. Roth, Eli Casdin, Keith Meister.
What are the main risk factors for Genedx Holdings Corp. stock?
Of WGSWW's 26 assessed filings, 0 were flagged high-risk, 20 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Genedx Holdings Corp.?
Recent forward-looking statements from Genedx Holdings Corp. include guidance on {"claim":"GeneDx Holdings Corp. may experience increased investor interest due to Goldman Sachs' disclosed stake.","enti.